Insider trade

CEO sold ~$240K of ADMA shares in the open market

Traded Nov 19, 2025 · Filed Nov 22, 2025

Why it stands out

The CEO of ADMA Biologics sold $240K of ADMA Biologics shares. The filing says it was made under a pre-arranged trading plan.

Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell

View the official recordSEC Form 4 — Statement of Changes in Beneficial Ownership

All the details

CEO$100K–$500KPre-arranged plan referenced

Classification

open market sale

Code S — open-market or private sale

Absolute commitment

~$240,000

Shares × reported transaction price

Timing vs results

14 days after results of Nov 5, 2025, 54 days before results of Jan 12, 2026

Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results

Planned / mechanical clue

Footnote references a pre-arranged trading plan (Rule 10b5-1)

Only flagged when a footnote says so; never inferred

After	Stock	S&P 500	Difference
7 days	+5.8%	+1.7%	+4.1%
30 days	+6.7%	+3.2%	+3.4%
90 days	−11.1%	+2.0%	−13.1%
180 days	−55.5%	+12.2%	−67.8%

Past results only. Not a forecast.

Transaction was effected pursuant to a Rule 10b5-1 trading plan entered into between the reporting person and Fidelity Brokerage Services LLC on December 5, 2024, as previously disclosed by the issuer.
The price reported in Column 4 is the price at which the shares were sold.

Filed 10mo ago

Traded Dec 15, 2025 · filed 2 days later

Derivative exercise or conversion — not an open-market buy.

Scheduled in advanceFiled 10mo ago

Scheduled in advanceFiled 10mo ago